Huntington beach
HUNTINGTON BEACH, California and AMSTERDAM, June 4, 2010 - Agendia, a world leader in molecular cancer diagnostics, today announced
that researchers from Agendia and leading academic centers in the U.S.
HUNTINGTON BEACH, California, and AMSTERDAM, April 29, 2010 - Today, at the 11th Annual Meeting of the American Society of Breast
Surgeons, Agendia, a world leader in molecular cancer diagnostics, announced
that Breast Cancer Research and Treatment has published an important study
demonstrating the benefit of adjuvant chemotherapy for patients with a
high-risk of breast cancer recurrence according to the MammaPrint test.
HUNTINGTON BEACH, California and AMSTERDAM, April 20, 2010 - Agendia, a world leader in molecular cancer diagnostics, announced today
it has closed an agreement with Ferrer inCode for the commercialization of
Agendia's FDA-cleared breast cancer recurrence test MammaPrint in Latin
America.
HUNTINGTON BEACH, California and AMSTERDAM, March 24, 2010 - Agendia, a world leader in molecular cancer diagnostics, today announced
that its breast cancer product offering, consisting of breast cancer
recurrence test MammaPrint(R), and TargetPrint(TM), has been expanded with
BluePrint (TM) to report important additional information on tumor subtypes.
HUNTINGTON BEACH, California and AMSTERDAM, March 17, 2010 - Agendia, a world leader in molecular cancer diagnostics, announced today
it will participate in the highly anticipated I-SPY 2 TRIAL for breast
cancer, set to launch at the first of nearly twenty research sites.
More News
- Agendia Receives New York State Laboratory Permit and Laboratory Accreditation by College of American Pathologists
- FDA Broadens Clearance for Agendia's MammaPrint(R)
- Agendia to Present Broad Array of Data at 2009 San Antonio Breast Cancer Symposium
- Medicare Administrator Establishes Reimbursement Coding Policy for Agendia's Breast Cancer Recurrence Test MammaPrint(R)
- Agendia Raises US $23 Million in Series E Financing
- FireScope 3.5 Delivers Management Reliability and Enhanced Virtualization Power
- Agendia’s Breast Cancer Recurrence Test MammaPrint Included in International St. Gallen Expert Consensus Recommendations
- Agendia Supports Genentech’s Citizen’s Petition Urging FDA to Hold In-Vitro Diagnostic Tests to One Set of Scientific and Regulatory Standards
- Agendia Opens CLIA-Registered U.S. Genomics Laboratory
- Agendia to Present Multiple Predictive and Prognostic Studies on Breast and Colorectal Cancers at ASCO Annual Meeting
- FireScope Receives Network Products Guide 2009 Product Innovation Award
- Agendia to Present at BioCentury’s Future Leaders in the Biotech Industry Conference
- Agendia Presents Data Supporting MammaPrint’s Predictive and Prognostic Power at 2009 St. Gallen Breast Cancer Conference
